Loading
A phase 3 trial of Busulfan and Treosulfan in Acute myeloid leukaemia, run by medac GmbH, completed.
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC) is a phase 3 interventional study registered as NCT00822393 by medac GmbH, with 570 participants recorded, started 2008-11-24 and reaching its primary completion in 2018-01-25. Interventions recorded: Busulfan, Treosulfan. Conditions recorded: Acute Myeloid Leukemia, Myelodysplastic Syndrome.
Linked to the drug Treosulfan because the registry names it among its interventions and Acute myeloid leukaemia among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Busulfan, Acute myeloid leukaemia and the tag pipeline.
Shares Treosulfan and the tag pipeline.
Shares Busulfan and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/